Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro

Anticancer Research

Volumn 17, Issue 1 A, 1997, Pages 99-103

  Volm, Manfred ^a   Koomägi, Reet ^a   Mattern, Juergen ^a   Stammler, Gerd ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Basic fibroblast growth factor; Drug resistance; Immunohistochemistry; Non small cell lung carcinomas; Receptors; Vascular endothelial growth factor

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CARCINOMA, NON-SMALL-CELL LUNG; DOXORUBICIN; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTOR 2; HUMANS; LUNG NEOPLASMS; LYMPHOKINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 1842408971     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ferrara N: The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 36: 127-137, 1995.
2. Fong GH, Rossant J, Gertsenstein M and Breitman ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66-70, 1995.
3. Dionne CA, Crumley G, Bellot F, Kaplow JM, Searfoss G, Ruta M, Burgess WH, Jaye M and Schlessinger J: Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors. EMBO J 9: 2685-2692, 1990.
4. Koomägi R, Mattern J and Volm M: Up-regulation of resistance-related proteins in human lung tumors with poor vascularization. Carcinogenesis 16: 2129-2133, 1995.
5. Volm M, Koomägi R and Mattern J: Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small cell lung carcinoma. Anticancer Res 16: 213-218, 1996.
6. Volm M, Bak M, Efferth T, Lathan B and Mattern J: Immunocytochemical detection of a resistance-associated glycoprotein in tissue culture cells, ascites tumors and human tumor xenografts by Mab 265/F4. Anticancer Res 8: 531-536, 1988.
7. Volm M, Mattern J and Samsel B: Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein, and glutathione S-transferase-π in human lung tumors. Cancer 71: 3181-3187, 1993.
8. Efferth T and Volm M: Immunocytochemical detection of oncoproteins in animal and human tumor lines with acquired or inherent multidrug resistance. Cancer Detect Prevent 16: 237-243, 1992.
9. Volm M, Mattern J, Stammler G, Royer-Pokora B, Schneider S, Weirich A and Ludwig R: Expression of resistance-related proteins in nephroblastoma after chemotherapy. Int J Cancer 63: 193-197, 1995.
10. Volm M, Drings P, Mattern J, Sonka J, Vogt-Moykopf I and Wayss K: Prognostic significance of DNA patterns and resistance-predictive test in non-small cell lung carcinoma. Cancer 56: 396-403, 1985.
11. Ferrara N, Houck K, Jakeman L and Leung DW: Molecular and biological properties of the vascular endothelial-growth-factor family of proteins. Endocrine Rev 13: 8-32, 1992.
12. Desoize B: Anticancer drug resistance and inhibition of apoptosis. Anticancer Res 14: 2291-2294, 1994.
13. Katoh O, Tauchi H, Kawaishi K, Kimura A and Satow Y: Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 55: 5687-5692, 1995.
14. Kolch W, Martiny-Baron G, Kieser A and Marme D: Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. Breast Cancer Res Treat 36: 139-155, 1995.
15. Ritkin DB and Moscatelly D: Recent developments of the cell biology of fibroblast growth factors. J Cell Biol 109: 1-6, 1989.
16. Goto F, Goto K, Weindel K and Folkman J: Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and formation of bovine capillary endothelial cells within collagen gels. Lab Invest 69: 508-517, 1993.
17. Baird A and Klagsbrun M: The fibroblast growth factor family. Ann NY Acad Sci 638: 403-477, 1991.
18. Toi M: Endothelial growth factors: a target for antiangiogenesis. Cancer J 8: 315-319, 1995.
19. 2 arrest and cell survival following ionizing radiation. Cancer Res 54: 5194-5197, 1994.
20. Huang A and Wright JA: Fibroblast growth factor mediated alterations in drug resistance, and evidence of gene amplification. Oncogene 9: 491-499, 1994.
21. Teicher BA: Hypoxia and drug resistance. Cancer Metast Rev 13: 139-168, 1994.
22. O'Dwyer PJ, Yao KS, Ford P, Godwin AK and Clayton M: Effects of hypoxia on detoxicating enzyme activity and expression in HT29 colon adenocarcinoma cells. Cancer Res 54: 3082-3087, 1994.
23. Rice GC, Hoy C and Schimke RT: Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. Proc Nat Acad Sci (Wash) 83: 5978-5982, 1986.
24. Mattern J, Kallinowski F, Herfarth C and Volm M: Association of resistance-related protein expression with poor vascularization and low levels of oxygen in human rectal cancer. Int J Cancer 66: 20-23, 1996.